Innovent Biologics (suzhou) Co. Ltd.

This study looks at how well the drug taletrectinib works in people with advanced ROS1-positive non-small cell lung cancer whose cancer has gotten worse after treatment with entrectinib. Researchers will follow 50 patients in real-world clinics to see if the drug shrinks tumors a…

This Phase 3 trial tests a new drug called IBI3003 against standard treatments (pomalidomide, bortezomib, daratumumab) in 255 people with multiple myeloma that has relapsed or become resistant. The goal is to see if IBI3003 helps patients live longer without the cancer getting wo…

This early-stage trial tests the safety and tolerability of a new drug called IBI3031 in 66 people with moderate-to-severe active thyroid eye disease. Participants will receive either the drug or a placebo by injection or infusion. The study aims to find the right dose and check …

This study tests a drug called IBI363 given before surgery for people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the drug helps shrink or eliminate the tumor before the operation. About 10 participants will receive IBI363, and resea…

This study tests a new drug combination (IBI3005) in about 282 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check safety and see if the treatment shrinks tumors. Participants will be closely monitored for side effects a…

This study tests a new drug called teprotumumab N01 against standard steroid treatment for active thyroid eye disease, a condition that causes eye bulging and discomfort. About 92 adults with moderate-to-severe symptoms will receive either the new drug or steroids to see which be…

This early-stage study tests a single injection of a new drug, IBI3016, in 30 Chinese adults with mild to moderate hypertension who are not currently on blood pressure medication. The main goal is to check safety and how the drug moves through the body, with a secondary look at i…

This early-stage study tests the safety of an experimental drug called IBI3033 in 16 adults with moderate-to-severe atopic dermatitis (eczema). Participants receive either the drug or a placebo over 12 weeks, with follow-up for 4 more weeks. The main goal is to check for side eff…

This Phase 1 trial compares a new insulin called IBI3035 to an existing long-acting insulin (Awiqli) in 144 healthy Chinese men. Researchers will measure how the body absorbs and responds to each drug after a single injection. The goal is to see if IBI3035 works similarly to Awiq…